Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Inventory (2017 - 2025)

RedHill Biopharma has reported Inventory over the past 9 years, most recently at $3.2 million for Q2 2025.

  • Quarterly Inventory fell 16.69% to $3.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Jun 2025, down 16.69% year-over-year, with the annual reading at $3.7 million for FY2024, 16.81% down from the prior year.
  • Inventory was $3.2 million for Q2 2025 at RedHill Biopharma, down from $3.7 million in the prior quarter.
  • Over five years, Inventory peaked at $14.3 million in Q1 2022 and troughed at $3.2 million in Q2 2025.
  • The 5-year median for Inventory is $8.2 million (2021), against an average of $8.2 million.
  • Year-over-year, Inventory surged 235.02% in 2021 and then tumbled 60.13% in 2023.
  • A 5-year view of Inventory shows it stood at $7.7 million in 2021, then skyrocketed by 42.97% to $11.0 million in 2022, then tumbled by 60.13% to $4.4 million in 2023, then dropped by 16.81% to $3.7 million in 2024, then fell by 13.2% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Inventory are $3.2 million (Q2 2025), $3.7 million (Q4 2024), and $3.8 million (Q2 2024).